The researchers developed a simple and “cost -effective blood test” capable of detecting Parkinson’s disease before symptoms appeared for a long time, according to a study.
About 153,000 people live with Parkinson’s in the UK, and scientists who conducted the research said the test “has” caused a revolution “in an early diagnosis of Parkinson’s disease,” they pave the way for time interventions and improve patients’ results. “
Parkinson’s is a gradual nervous condition in which neurons are lost in the brain over time. This reduces chemical dopamine that plays an important role in controlling movement.
This new test, which costs 80 pounds sterling, analyzes small pieces of genetic materials known as RNA Transport Fragments (TRFS) in the blood, focusing on the frequent RNA sequence that accumulates in Parkinson’s patients.
It is also seen a parallel decrease in the Metochondria RNA, which deteriorates with the progress of the disease. Mitochondria is present in cells and power generation.
By measuring the percentage between these vital indicators, the researchers said the test “provides an accurate, non -surgical and rapid diagnostic tool at reasonable prices, providing hope for early interventions and treatments that can change the course of the disease.”
On a scale where 1st degree indicates a perfect test while 0.5 shows that the test is not better than stirring the currency, and the test record is 0.86, according to the Times.
The best clinical tests currently used on patients who offer early signs of the disease. Register 0.73, according to the study published in the magazine The aging of nature.
The test uses the same PCR technology used during the epidemic to confirm Covid cases. It works by amplifying the genetic materials that are targeted, allowing to be detected.
“This discovery represents a great progress in our understanding of Parkinson’s disease and provides a simple blood test as a tool for early diagnosis,” said Professor Hermona Soric of the Hebrew University of Jerusalem, who supervised the study. “By focusing on TRFS, we have opened a new window in the molecular changes that occur in the early stages of the disease.”
“This research represents a new angle to explore in the search for a biological brand of Parkinson. In this case, the brand can be recognized and measured in the blood, making it attractive to a friendly diagnostic test for the patient in the future,” said Professor David Dixter, Parkinson’s research director in the United Kingdom.
“More work is needed to continue testing this possible test and checking it, especially understanding how it can distinguish between other conditions that have similar early signs on Parkinson.”
The study was led by the PhD, Nimrod, running under the supervision of Professor Sork, at the Edmund and Laila Safra Center for Brain Science (ELSC) and the Alexander Silberman in Life Sciences, at the Hebrew University, in cooperation with Dr. Edo, the role from the Shar Zedic Medical Center, from the University of Terlay and Doctor.
